October is the season of harvest. After winning the "Best Market Value Management Listed Company" award last year, the "14th China Listed Company Competitiveness and Credibility Survey and Selection" event was held in Chengdu, Sichuan on October 18th. Cheng Yi Pharmaceutical was awarded the "Best Growth Potential Listed Company" award.
This selection and summit forum is hosted by the Nanjing Volkswagen Securities News in Jiangsu. Li Zhongwu, a member of the Party Committee and Deputy General Manager of Nanjing Newspaper Media Group, stated in his speech that there are currently over 3600 listed companies in Shanghai and Shenzhen, with 155 million investors. Listed companies have become the backbone of China's economic development. The "Competitiveness and Credibility Survey and Selection of Listed Companies" has been successfully held for fourteen sessions. For the past 10 years, this activity has been accompanied by the Chinese stock market, based on small and medium-sized investors, committed to 'telling the truth and having good value', promoting the value discovery and integrity construction of listed companies, striving to provide investors with a true and transparent listed company, a standardized governance listed company, and an honest and responsible listed company. It has attracted widespread attention from experts, scholars, investment institutions, listed companies, and many investors.
The award speech given by the organizing committee's selection experts to Chengyi Pharmaceutical is:
Cheng Yi Pharmaceutical has outstanding growth potential, with revenue and profit growth surpassing industry levels; The management team is highly innovative and has made groundbreaking breakthroughs in multiple fields; The company's main business is outstanding, and its products and services have a strong competitive advantage.
The selection experts of the organizing committee believe that the main business is the main channel for profit growth of listed companies, which can clearly reflect the competitiveness level of listed companies. "Yearly increasing profits" is the best performance of performance. Taking Cheng Yi Pharmaceutical as an example, the company's net profit increased by 1.57% year-on-year in 2017, 39.97% year-on-year in 2018, and 51.68% year-on-year in the first half of 2019. The only source of its net profit is pharmaceutical product manufacturing. Focusing on the pharmaceutical manufacturing industry and wholeheartedly seeking the welfare of people's health is Cheng Yi Pharmaceutical's "original intention and mission"; The main reason for Cheng Yi Pharmaceutical's continuous success in the highly competitive medical industry is to follow the path of product differentiation research and development, implement marketing reform, constantly break through the bottleneck of growth, constantly expand the growth space, always maintain the development path with marine biological pharmacy as the main feature, and ensure the sustainable growth of profits.
Ms. Chen Xueqin, the representative of the company's securities affairs, attended the meeting to receive the award. Representatives from 101 listed companies across the country attended the award ceremony and summit forum. More than 30 media reporters from across the country reported on the grand ceremony and summit. (Wu Fengxu)